Cytokines are critical for normal
cell growth and immunoregulation but also contribute to growth of malignant
cells and drive immune-mediated disease. A large subset of immunoregulatory
cytokines uses the type I and type II cytokine receptors and pharmacological
targeting of these cytokines/cytokines receptors has proven to be efficacious
in treating immune and inflammatory diseases. These receptors rely on Janus
family of kinases (Jaks) for signal transduction. Recently the first Jak inhibitor
(jakinib) has been approved by the FDA and a second has been recommended for
approval. Many other Jakinibs are likely to follow and in this brief review, we
will discuss the state-of-the art of this new class of pharmacological agents.
Source: Jakinibs: a new class of
kinase inhibitors in cancer and autoimmune disease. Kontzias A, Kotlyar A,
Laurence A, Changelian P, O'Shea JJ. Curr Opin Pharmacol. 2012
Aug;12(4):464-70.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire